Recommended Reading on Thrombosis

ESC Working Group on Thrombosis

Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial

European Heart Journal

Urgent surgery vs fibrinolytic therapy for left-sided prosthetic valve thrombosis: a randomized trial

European Heart Journal

Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis

European Heart Journal

Plaque erosion risk and <em>JAK2</em> V617F variant

European Heart Journal

Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy A clinical consensus statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care (ACVC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA) of the ESC, the ESC Working Group on Cardiovascular Pharmacotherapy and the European Association for Haemophilia and Allied Disorders (EAHAD)

European Heart Journal - Cardiovascular Pharmacotherapy

Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis

European Heart Journal

Evolution of left ventricular thrombus on serial cardiovascular magnetic resonance imaging

European Heart Journal - Cardiovascular Imaging

The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice

European Heart Journal

Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials

European Heart Journal

Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial

European Heart Journal - Cardiovascular Pharmacotherapy

Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis

European Heart Journal - Cardiovascular Pharmacotherapy

Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score

European Heart Journal

Semaglutide and cardiovascular outcomes by baseline HbA<sub>1c</sub> in diabetes: the SUSTAIN 6 and PIONEER 6 trials

European Heart Journal

Low-dose colchicine for atherosclerosis: long-term safety

European Heart Journal

Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h

European Heart Journal

Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study

European Heart Journal - Cardiovascular Pharmacotherapy

Platelet biology and function: plaque erosion vs. rupture

European Heart Journal

Inflammation in acute myocardial infarction: the good, the bad and the ugly

European Heart Journal

Factor XIa inhibitors: collecting the clinical evidence

European Heart Journal - Cardiovascular Pharmacotherapy

Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials

European Heart Journal - Cardiovascular Pharmacotherapy

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

European Heart Journal

Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis

European Heart Journal

<em>Staphylococcus aureus</em> endocarditis: distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves

European Heart Journal

Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study

European Heart Journal